A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE)

ovartis Pharma Services Inc.0 个研究点目标入组 4 人开始时间: 2023年7月25日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•-Written informed consent must be obtained before any assessment is performed.
•Male and female patients = 18 years of age.
•Diagnosis of HS = 1 year prior to baseline.
•Patients with moderate to severe HS defined as:
•A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND
•Inflammatory lesions should affect at least 2 distinct anatomic areas
•Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.

•Total fistulae count = 20 at baseline.
•Any other active skin disease or condition that may interfere with assessment of HS.
•Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.
•Use or planned use of prohibited treatment. Washout periods detailed in the protocol have to be adhered to.
•History of hypersensitivity to any of the study drug constituents.
•History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
•Pregnant or lactating women.

发起方

ovartis Pharma Services Inc.